Articles On Immutep (ASX:IMM)

Australian retail sales experienced a 0.8% decline last month, as reported by the Australian Bureau of Statistics. This result came as a surprise to markets, which had anticipated a steady performance for June following a robust 0.7% gain i...

  First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma Immutep (ASX:IMM; NASDAQ:IMMP) announced that the first patient has been dosed in the Chemotherapy-free Combination Phase II Trial Ta...

The ASX looks set to stoop lower for the last session of the week. Investors are warned to keep an eye open for today’s release of the latest retail sales figures as the rest of Australia prepares for next week’s RBA interest rate decisi...

28 Jul 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Pointerra (ASX:3DP) and Zeus Resources (ASX:ZEU).

ASX healthcare shares are currently underperforming ASX 200 shares, but over the longer term, they’ve grown twice as fast. The S&P/ASX 200 Index (ASX: XJO) is up 7.1% over the past year, while the S&P/ASX 200 Health Care Index (AS...

The All Ordinaries Index (ASX: XAO) is up a healthy 4% in 2023, while ASX All Ords share Immutep Ltd (ASX: IMM) has surged 17% over this same time. And the ASX biotech company could have more potential outperformance to come. Here’s w...

The Bubs Australia Ltd (ASX: BUB) share price is ending the week deep in the red. In morning trade, the embattled infant formula company’s shares are down 11% to 16 cents. Why is the Bubs share price sinking? Investors have been hitting...

ASX 200 benchmark climbs 0.65% despite a sour lead-in from Wall Street and Europe. Real Estate sector banks solid wins after shopping centres put on a big day.  Forrestania Resources hits 162% on thick pegmatite news, but the ASX has asked...

  Marc Voigt – Executive Director & CEO – Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for cancer and autoimmune diseases.

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

20 Jun 2023 - Immutep Limited (ASX:IMM), a clinical-stage biotechnology company focusing on LAG-3 immunotherapies for cancer and autoimmune diseases, has received a new patent from…

The ASX 200 climbed 0.86% today, after the RBA said it wants you all to get fired. Energy stocks climb 1.94% after I dared to turn my heater on this morning. Brightstar is thiiiis close to actual gold production, up 30% today as a result....

A couple of ASX lithium shares have been catching the eye on Tuesday with some strong gains. Let’s take a look and see what’s getting investors excited today: Leo Lithium Ltd (ASX: LLL) The Leo Lithium share price is up 9% to $1.17. Th...

Austco Healthcare wins St Paul’s Hospital in Canada worth $7.4m Next Science announced a new CEO AVITA Medical and Genetic Signatures announce new CFOs   Digital health company Austco Healthcare (ASX:AHC) surged by as high as 30% this mor...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. The benchmark index is currently up 0.25% to 7,180 points. Four ASX shares that are climbing more than most today are listed below. Here’s why...

I believe that the two ASX shares I’m going to write about in this article have the potential to deliver total returns of over 100% in the next three years. While small businesses naturally have more room to grow compared to large busine...

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

ASX All Ords retail share Universal Store Holdings Ltd (ASX: UNI) crashed by almost 25% in just two weeks and three company directors have enthusiastically bought the dip. One took a ‘go hard or go home’ approach and ploughed more than $1...

All stocks, no matter how well they perform in the long run, will have short-term dips. That’s why it’s imperative to not get distracted by these fluctuations.  In fact, if the quality of the business’ future prospects hasn’t changed then...

The Adairs Ltd (ASX: ADH) share price suffered a big sell-off last week – it fell around 15% on Friday. It’s down 28% from 22 May 2023 and it has dropped 45% from 1 February 2023. The ASX All Ordinaries Index (ASX: XAO) share has been...

If you have room for some new portfolio additions in June, then it could be worth considering the three ASX growth shares listed below. Here’s what you need to know about these buy-rated shares: Aristocrat Leisure Limited (ASX: ALL) The...

Several new health-focused funds joined the biotech’s register including Platinum.

If you’re searching for a passive income boost, then you may want to check out the ASX dividend stocks listed below. Analysts have named these dividend stocks as buys and tipped them to provide very large yields in the near term. Hereâ€...

ASX retail shares are falling amid news today of a 5.75% hike to the minimum wage and concern among investors about the rising cost of living now affecting retail sales in 2023. Earlier today the Fair Work Commission announced a 5.75% bum...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on track to end the week on a positive note. At the time of writing, the benchmark index is up 0.25% to 7,129.3 points. Four ASX shares that have failed to follow the market high...

The Bubs Australia Ltd (ASX: BUB) share price is falling on more disappointing sales data from China and amid a move that could see four board members canned. Bubs founder and former CEO Kristy Carr is leading a group of shareholders calli...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

The ASX 200 fell 1.37%, and the bad news kept piling up all day Inflation data knee-capped the market mid-morning, because rate hikes are on the way Two Small Caps hit triple-figure home runs today, which is kinda amazing   Welp… that was...

The immunotherapy biotech had brokers Bell Potter, Jefferies and Wilsons in its corner on Wednesday.

The S&P/ASX 300 (ASX: XKO) has climbed 0.78% in the last two days, but this ASX 300 lithium share is far outperforming the index. The Leo Lithium Ltd (ASX: LLL) share price is up 29% this trading week and is now at 93.2 cents. In toda...

Immutep (ASX:IMM) has announced it has entered into an agreement under which Charles River will conduct a GLP toxicology study for IMP761.

ASX lithium share Leo Lithium Ltd (ASX: LLL) is soaring higher today, up 13.8% in early trade. Shares in the S&P/ASX 300 Index (ASX: XKO) lithium stock closed Friday trading for 72.5 cents. In early trade on Monday, shares are swapping...

ShareCafeThe Week that Was: May 22-26, 2023 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so, her...

It has been another busy week for Australia’s top brokers. This has led to the release of a large number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think th...

ASX health stocks have fallen in the past five days in line with broader markets Volpara Health Technologies reports strong FY23 results, above Morgan’s expectations Pharmaxis reports positive trial results in potential breakthrough treatm...

The S&P/ASX 200 Index (ASX: XJO) tumbled on Thursday, falling 1.05% to close at 7,138.2 points. The market’s suffering came amid continued concerns of the United States’ rapidly approaching debt ceiling, as my Fool colleague Bernd...

The market is continuing its downward trend for today, with the ASX200 around 0.8 per cent lower in early afternoon trade. Diversified miner, Sandfire Resources (SFR), has produced first copper concentrate at its Motheo copper mine in Bo...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and dropped into the red. At the time of writing, the benchmark index is down 0.85% to 7,151.5. Four ASX shares that are not letting that stop them from rising today...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Biotechnology company Immutep (ASX: IMM) has safely dosed the first patient at a European clinical site for its integrated Phase II/III AIPAC-003 trial to treat metast...

Immutep (IMM) enrols and doses its first patient at its European clinical site for its integrated Phase II/III AIPAC-003 trial The trial aims to evaluate the effectiveness of Immutep’s drug candidate, eftilagimod alpha (efti), in combi...

The Webjet Limited (ASX: WEB) share price has been on form this week. So much so, the online travel agent’s shares hit a new 52-week high on Wednesday. This means the company’s shares are now up almost 23% since the start of the year....

The ASX is expected to fall today on the back of overnight losses across other global markets, namely Europe and the US. Here are some ASX-listed companies to watch out for on Thursday: The first patient in Immutep’s (IMM) AIPAC-003 p...

ASX lithium share Delta Lithium Ltd (ASX: DLI) may not be a household name, but it appears it is attracting interest from billionaire investors. Delta Lithium shares have soared nearly 37% year to date and 44% in the last month. So what...

The average Australian’s superannuation balance leaves much to be desired for one seeking a comfortable retirement. Fortunately, there’s a solution. Let’s dive into what anyone hoping to enter retirement without a large super balance c...

On Wednesday, the S&P/ASX 200 Index (ASX: XJO) was out of form and dropped into the red. The benchmark fell 0.6% to 7,213.8 points. Will the market be able to bounce back from this on Thursday? Here are five things to watch: ASX 200...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

The S&P/ASX 200 Index (ASX: XJO) struggled in Wednesday’s session, falling 0.63% to close at 7,213.8 points. That was despite a strong performance from the S&P/ASX 200 Energy Index (ASX: XEJ), which lifted 0.7% on the back of ri...

The S&P/ASX 200 Index (ASX: XJO) has dropped into the red on Wednesday. In afternoon trade, the benchmark index is down 0.5% to 7,221.4 points. Four ASX shares that are not letting that hold them back are listed below. Here’s why th...

Patry receives positive toxicology reports on PAT-DX1 Immutep says triple combination trial of Efti shows it is well tolerated Clarity Pharma is now advancing to cohort 2   Patrys receives positive report Therapeutic antibody development...